Pharming Group's Involvement in Rare Disease Summit
Pharming Group N.V. is taking a significant step in the world of rare diseases by participating in an invitation-only event dedicated to addressing challenges and advancements in this sector. The Oppenheimer Movers in Rare Disease Summit is an excellent opportunity for Pharming to engage with other innovative companies and key investors who share a commitment to improving the lives of those afflicted by rare conditions.
Insights into Hereditary Angioedema
At this year’s summit, Anurag Relan, M.D., the Chief Medical Officer of Pharming, will lead a fireside chat focused specifically on the hereditary angioedema (HAE) market. This discussion, scheduled for 1:50 pm ET, will delve into the latest insights and developments surrounding HAE, providing attendees with valuable information about advancements in treatment options and patient care.
Schedule a Meeting with Pharming's Management
For investors and stakeholders keen on engaging further with Pharming's management team, one-on-one meetings can be arranged through the company’s Investor Relations department. It is a perfect avenue for discussing investment opportunities and understanding more about Pharming's innovative solutions for rare diseases.
About Pharming Group N.V.
Pharming Group N.V. is a pioneering biopharmaceutical company focused on transforming lives impacted by rare and severe diseases. Specializing in the development and commercialization of a diverse portfolio of medicines, including both small molecules and biologics, Pharming is dedicated to addressing unmet medical needs. The company's headquarters are located in Leiden, the Netherlands, yet a considerable number of its employees operate out of the U.S., reflecting its global outreach and commitment to innovation in healthcare.
Connect with Pharming for More Information
To learn more about Pharming's groundbreaking work, interested parties are encouraged to visit their official website. Here, you can dive into detailed descriptions of their latest treatments and scientific endeavors. Furthermore, being active on LinkedIn allows for updates on their ongoing projects and collaborations within the industry.
Contacting Pharming Group
For anyone seeking additional public information or specific inquiries, Pharming establishes a clear line of communication. The Investor Relations team, led by Michael Levitan, is available to assist with any questions regarding investments and corporate communications. Alternatively, Pharming’s media relations can provide insights into their projects and strategic directions.
Frequently Asked Questions
What is the purpose of the Oppenheimer Movers in Rare Disease Summit?
The summit aims to unite innovative companies and investors to discuss advancements in the treatment and understanding of rare diseases.
Who will represent Pharming at the summit?
Anurag Relan, M.D., the Chief Medical Officer of Pharming, will lead discussions focused on hereditary angioedema.
How can investors get in touch with Pharming?
Investors can schedule meetings with Pharming’s management by contacting their Investor Relations department directly.
What innovative solutions is Pharming developing?
Pharming is focused on developing a portfolio of innovative medicines that address rare and debilitating diseases.
Where can I find more information about Pharming Group?
More information can be found on Pharming's official website and their LinkedIn page.